

July 13, 2007

Announcing...

**Rh₀(D) Immune Globulin (Human)
RhoGAM[®] and MICRhoGAM[®] Ultra-Filtered PLUS**

Dear Customer,

Ortho-Clinical Diagnostics, Inc. (OCD) is pleased to announce the availability of Rh₀(D) Immune Globulin (Human) **RhoGAM[®] and MICRhoGAM[®] Ultra-Filtered PLUS**. Since its introduction in 1968, RhoGAM, a leader in the prevention of Hemolytic Disease of the Newborn (HDN), has experienced numerous product improvements.

Ortho-Clinical Diagnostics' long and outstanding record of safety places RhoGAM Ultra-Filtered apart from all other Rh Immune Globulins – ***there is only one RhoGAM***. This legacy of safety and quality continues with the introduction RhoGAM and MICRhoGAM Ultra-Filtered PLUS, which offer the following enhancements:

Safety:

- Replaced animal-derived Polysorbate 80 with vegetable-derived Polysorbate 80
- Barcode added to pouch (Linear 128 format)
- New viral inactivation step
- Data to support viral inactivation of West Nile Virus
- Data to support viral removal of Hepatitis A Virus

New “Easy to Read” Package Insert:

- Conforms to new Food and Drug Administration (FDA) guidance
- New “Dosing Frequency” section
- New table summarizing the total viral clearance capability of the manufacturing process

In addition, OCD is introducing an improved shipping container for the RhoGAM and MICRhoGAM Ultra-Filtered PLUS products.

The table below lists the current and new product codes:

Current Product Codes RhoGAM Ultra-Filtered	<i>New Product Codes</i> RhoGAM Ultra-Filtered PLUS	<i>New National Drug Code (NDC #)</i>	Package Size
780701	780501	0562-7805-01	1 Syringe
780710	780505	0562-7805-05	5 Syringe
780715	780525	0562-7805-25	25 Syringe
Current Product Codes MICRhoGAM Ultra-Filtered	<i>New Product Codes</i> MICRhoGAM Ultra-Filtered PLUS	<i>New National Drug Code (NDC #)</i>	Package Size
780801	780601	0562-7806-01	1 Syringe
780810	780605	0562-7806-05	5 Syringe
780815	780625	0562-7806-25	25 Syringe

All future production will be of RhoGAM and MICRhoGAM Ultra-Filtered PLUS products. The table below provides the anticipated availability dates from OCD. Your OCD authorized distributor should be contacted to obtain their anticipated availability dates for RhoGAM and MICRhoGAM Ultra-Filtered PLUS products. Credit for current products will **not** be issued when the new products are available.

Product Name	<i>Anticipated Date of Availability from OCD</i>
RhoGAM Ultra-Filtered PLUS	August 6, 2007
MICRhoGAM Ultra-Filtered PLUS	September 4, 2007

Please notify your purchasing organizations regarding the updates to the product codes listed in the table on the previous page. Advance notification may be needed to allow for the transition to the RhoGAM/MICRhoGAM Ultra-Filtered PLUS products. All existing purchase orders of the current product codes **MUST** be modified to reflect the new product codes. Questions regarding orders (quantity, PO #, frequency, etc.) should be placed to your distributor.

Ortho-Clinical Diagnostics, is committed to providing you with high quality products and services. If you have any questions, call your Distributor or call OCD Customer Technical Support at 1-800-421-3311 (Options 2, 1, 1) regarding technical information.

Sincerely,



Mark Straley
 Vice President, World Wide Marketing
 Ortho-Clinical Diagnostics, Inc.

Important Safety Information

RhoGAM[®] and MICRhoGAM[®] Ultra-Filtered PLUS are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent. RhoGAM and MICRhoGAM are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. RhoGAM and MICRhoGAM contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Patients who receive RhoGAM or MICRhoGAM for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction.